Frequency And Severity Of Thrombocytopenia In Patients With Liver Cirrhosis
DOI:
https://doi.org/10.69980/ajpr.v29i1.808Keywords:
Platelet Count, Thrombocytopenia, Child-Pugh Classification, Haematological Abnormalities, Liver Cirrhosis, Portal HypertensionAbstract
Objective: To Establish The Rate And Intensity Of Thrombocytopenia, In Patients With Liver Cirrhosis.
Methodology: The Study Was Conducted From January 2025 To June 2025, And The Setting Of The Study Was On Gims Gambat Where 247 Patients With Cirrhosis Were Sampled Using Consecutive Sampling Technique. Clinical, Biochemical And Ultrasound Criteria Were Used To Diagnose Liver Cirrhosis. The Platelet Counts Were Calculated In Order To Categorize Thrombocytopenia Into Mild, Moderate, Or Severe Thrombocytopenia. The Demographic And Clinical Data Were Captured And Statistical Analysis Was Carried Out Using Spss 26 With Chi-Square Test And Considered Significant At P 0.05.
Results: The Age Of 247 Patients With Cirrhosis Was 40.46± 12.29 Years And 55.1% Of The Patients Were Male. Thrombocytopenia Was Found In 36.8% Of Patients. Individuals Who Had Thrombocytopenia Were Much Younger In Comparison To Those Who Did Not (P=0.0001). Thrombocytopenia Was Significantly Correlated With Child-Pugh Class (P= 0.0001), Gender (P= 0.068) And Length Of Cirrhosis Had No Significant Correlation (P= 0.428).
Conclusion: This Research Has Indicated That Thrombocytopenia Is A Very Common And Clinically Notable Occurrence In Chronic Liver Disease And Its Severity May Rise With Advancement Of Hepatic Dysfunction. Identifying Its Patterns Is Critical In The Determination Of The Risk Of Bleeding And The Design Of Invasive Procedures. Detection Of Thrombocytopenia Earlier And Proper Supervision Can Help To Make Clinical Decisions In A Safer Way And Enhance The General Management Of Liver Disease Patients On Their Chronic Conditions.
References
1. Asrani Sk, Devarbhavi H, Eaton J, Kamath Ps. Burden Of Liver Diseases In The World. J Hepatol. 2019;70(1):151-71.
2. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee Rp, Trebicka J, Et Al. Easl Clinical Practice Guidelines For The Management Of Patients With Decompensated Cirrhosis. J Hepatol. 2018;69(2):406-60.
3. Greer Jp, Arber Da, Glader B, List Af, Means Rt Jr, Paraskevas F, Rodgers Gm. Wintrobe's Clinical Hematology. Asia Book Registry; 2019.
4. Afdhal N, Mchutchison J, Brown R, Jacobson I, Manns M, Poordad F, Et Al. Thrombocytopenia Associated With Chronic Liver Disease. J Hepatol. 2008;48(6):1000-7.
5. Drolz A, Horvatits T, Roedl K, Rutter K, Staufer K, Kneidinger N, Et Al. Coagulation Parameters And Major Bleeding In Critically Ill Patients With Cirrhosis. Hepatology. 2016;64(2):556-68.
6. Marot A, Henrion J, Knebel Jf, Moreno C, Deltenre P. Alcoholic Liver Disease Confers A Worse Prognosis Than Hcv Infection And Non-Alcoholic Fatty Liver Disease Among Patients With Cirrhosis: An Observational Study. Plos One. 2017;12(10):E0186715.
7. Mehmood Chz, Shah Zh, Sajad Q, Farooq N. Frequency Of Thrombocytopenia And Its Severity Among Patients Of Chronic Liver Disease Presenting To A Tertiary Care Hospital. Pak J Med Health Sci. 2022;16(1):155-6.
8. Abbas Mu, Sardar J, Asim M, Khan R, Khan S, Jaffar G. Frequency Of Thrombocytopenia In Patients With Chronic Liver Diseases In A Tertiary Care Hospital. Pak J Med Health Sci. 2022;16:739-41.
9. Chen H, Liu L, Qi X, He C, Wu F, Fan D, Et Al. Efficacy And Safety Of Anticoagulation In More Advanced Portal Vein Thrombosis In Patients With Liver Cirrhosis. Eur J Gastroenterol Hepatol. 2016;28(1):82-9.
10. Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, Et Al. Impact Of Portal Hemodynamics On Doppler Ultrasonography For Predicting Decompensation And Long-Term Outcomes In Patients With Cirrhosis. Scand J Gastroenterol. 2016;51(2):236-44.
11. Neunert C, Terrell Dr, Arnold Dm, Buchanan G, Cines Db, Cooper N, Et Al. American Society Of Hematology 2019 Guidelines For Immune Thrombocytopenia. Blood Adv. 2019;3(23):3829-66.
12. An H, Li L, Liu Z, Zhang P, Wu S, Han X, Et Al. Low Thyroid Function Is Associated With An Increased Risk Of Advanced Fibrosis In Patients With Metabolic Dysfunction-Associated Fatty Liver Disease. Bmc Gastroenterol. 2023;23(1):3.
13. Orme Me, Bentley R, Marcella S, Peck-Radosavljevic M, Perard R, Wedemeyer H, Et Al. Systematic Review With Meta-Analysis: Efficacy And Safety Of Lusutrombopag For Severe Thrombocytopenia In Patients With Chronic Liver Disease Undergoing Invasive Procedures. Adv Ther. 2022;39(9):4169-88.
14. charf Re. Thrombocytopenia And Hemostatic Changes In Acute And Chronic Liver Disease: Pathophysiology, Clinical And Laboratory Features, And Management. J Clin Med. 2021;10(7):1530.
15. Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Et Al. Practice Guidelines Of The Central European Hepatologic Collaboration (Cehc) On The Use Of Thrombopoietin Receptor Agonists In Patients With Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med. 2021;10(22):5419.
16. Villa E, Bianchini M, Blasi A, Denys A, Giannini Eg, De Gottardi A, Et Al. Easl Clinical Practice Guidelines On Prevention And Management Of Bleeding And Thrombosis In Patients With Cirrhosis. J Hepatol. 2022;76(5):1151-84.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 American Journal of Psychiatric Rehabilitation
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License permitting all use, distribution, and reproduction in any medium, provided the work is properly cited.
